Trial Profile
Evaluation of Safety and Efficacy Through Post Market Surveillance for Infanrix, the DTaP Mixed Vaccine.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 07 Aug 2009 Actual patient number (1258) added as reported by ClinicalTrials.gov.
- 28 May 2009 Actual end date changed from Apr 2008 to Jul 2008 as reported by ClinicalTrials.gov.
- 21 May 2009 New trial record